Novavax Historical Financial Ratios
| NVAX Stock | USD 13.01 1.39 9.65% |
Novavax is lately reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 0.0 will help investors to properly organize and evaluate Novavax financial condition quickly.
Novavax |
About Novavax Financial Ratios Analysis
NovavaxFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novavax investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novavax financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novavax history.
Novavax Financial Ratios Chart
Novavax financial ratios usually calculated using numerical values taken directly from Novavax financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Novavax. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Novavax's ROIC is fairly stable compared to the past year. Days Of Inventory On Hand is likely to rise to 57.18 in 2024, whereas Price To Sales Ratio is likely to drop 0.47 in 2024. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Novavax stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novavax sales, a figure that is much harder to manipulate than other Novavax multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Novavax dividend as a percentage of Novavax stock price. Novavax dividend yield is a measure of Novavax stock productivity, which can be interpreted as interest rate earned on an Novavax investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Novavax's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's ROIC is fairly stable compared to the past year. Days Of Inventory On Hand is likely to rise to 57.18 in 2024, whereas Price To Sales Ratio is likely to drop 0.47 in 2024.
| 2023 | 2024 (projected) | Dividend Yield | 0.007475 | 0.006645 | Price To Sales Ratio | 0.49 | 0.47 |
Novavax fundamentals Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.14 | 13.49 | 9.29 | 0.5 | 0.49 | 0.47 | |
| Ptb Ratio | (0.52) | 10.23 | (30.27) | (1.27) | (0.67) | (0.64) | |
| Days Sales Outstanding | 146.69 | 201.08 | 144.88 | 18.8 | 110.29 | 97.33 | |
| Book Value Per Share | (7.72) | 10.9 | (4.73) | (8.11) | (7.11) | (6.76) | |
| Free Cash Flow Yield | (1.44) | (0.0151) | 0.0249 | (0.63) | (1.61) | (1.52) | |
| Invested Capital | (1.73) | 1.09 | (1.29) | (0.87) | (0.27) | (0.29) | |
| Operating Cash Flow Per Share | (5.67) | (0.74) | 4.34 | (5.32) | (7.12) | (7.48) | |
| Pb Ratio | (0.52) | 10.23 | (30.27) | (1.27) | (0.67) | (0.64) | |
| Ev To Sales | 18.16 | 13.01 | 8.36 | 0.0104 | 0.19 | 0.18 | |
| Free Cash Flow Per Share | (5.75) | (1.69) | 3.57 | (6.51) | (7.7) | (8.09) | |
| Roic | (0.87) | (0.32) | (16.76) | 7.7 | 0.8 | 0.84 | |
| Net Income Per Share | (5.4) | (7.43) | (23.44) | (8.42) | (5.41) | (5.68) | |
| Sales General And Administrative To Revenue | 1.0 | 1.84 | 0.31 | 0.26 | 0.35 | 0.33 | |
| Research And Ddevelopement To Revenue | 6.1 | 1.57 | 2.21 | 0.77 | 0.67 | 0.63 | |
| Capex To Revenue | (0.0995) | (0.11) | (0.0501) | (0.0582) | (0.0598) | (0.0628) | |
| Cash Per Share | 3.27 | 12.35 | 20.36 | 17.1 | 5.75 | 8.84 | |
| Pocfratio | (0.7) | (150.86) | 32.96 | (1.93) | (0.67) | (0.71) | |
| Interest Coverage | (9.89) | (27.52) | (79.83) | (32.43) | (28.79) | (30.23) | |
| Capex To Operating Cash Flow | 0.0136 | 1.28 | (0.18) | 0.22 | 0.082 | 0.12 | |
| Pfcf Ratio | (0.69) | (66.05) | 40.1 | (1.58) | (0.62) | (0.65) | |
| Income Quality | 1.03 | 0.1 | (0.19) | 0.63 | 1.32 | 0.86 | |
| Roe | 0.7 | (0.68) | 4.96 | 1.04 | 0.76 | 1.3 | |
| Ev To Operating Cash Flow | (2.48) | (145.42) | 29.67 | (0.04) | (0.26) | (0.27) | |
| Pe Ratio | (3.68) | (0.74) | (15.01) | (6.1) | (0.89) | (0.93) | |
| Return On Tangible Assets | (1.24) | (1.12) | (0.3) | (0.71) | (0.31) | (0.33) | |
| Ev To Free Cash Flow | (2.45) | (63.67) | 36.1 | (0.0327) | (0.24) | (0.25) | |
| Earnings Yield | (0.51) | (0.27) | (1.36) | (0.0666) | (1.13) | (1.07) | |
| Intangibles To Total Assets | 0.33 | 0.0892 | 0.0529 | 0.0559 | 0.0687 | 0.0653 | |
| Net Debt To E B I T D A | (1.75) | 0.56 | 0.63 | 1.24 | 0.8 | 0.84 | |
| Current Ratio | 3.77 | 3.88 | 0.9 | 0.69 | 0.7 | 0.66 | |
| Tangible Book Value Per Share | (10.07) | 8.45 | (6.56) | (9.73) | (8.38) | (7.96) | |
| Receivables Turnover | 2.49 | 1.82 | 2.52 | 19.41 | 3.31 | 5.82 | |
| Graham Number | 30.62 | 42.68 | 49.93 | 39.19 | 29.43 | 56.05 | |
| Shareholders Equity Per Share | (7.72) | 10.9 | (4.73) | (8.11) | (7.11) | (6.76) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.05) | Revenue Per Share 8.726 | Quarterly Revenue Growth 0.159 | Return On Assets (0.16) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.